Fig. 5
A In vivo fluorescence imaging of 8505C tumor-bearing nude mice at 0 h, 1 h, 8 h and 24 h after tail vein administration of DiR-labeled blank-Exos/iRGD-Exos. Black circle indicates the tumor site. B Quantitative analysis of the tumor fluorescence intensity of the in vivo images. C In vivo SPECT/CT imaging of 8505C tumor-bearing nude mice after intravenous injection of different drug combinations (Na131I, blank-Exos-131I, and iRGD-Exos-131I) at 0.5 h, 24 h, 72 h and 96 h postinjection. White circle indicates the tumor site. D Quantitative analysis of the radiation counts at the tumor site. *P < 0.05, **P < 0.01, ***P < 0.001. # indicates P < 0.01 compared to the Na131I group. & indicates P < 0.001 compared to the Na131I group